Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 07, 2026 07:00 ET | Source: Soleo Health Holdings, Inc.

Soleo Health Relocates Denver Specialty Pharmacy to Support Continued Growth

FRISCO, Texas and CENTENNIAL, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today the opening...
April 02, 2026 11:00 ET | Source: Crohn's and Colitis Canada

Le programme de bourses d'études MII d’AbbVie fête ses 15 ans : les candidatures sont ouvertes pour 2026

TORONTO, 02 avr. 2026 (GLOBE NEWSWIRE) -- Crohn et Colite Canada et AbbVie sont heureux d'annoncer l'ouverture des candidatures pour le Programme de bourses d'études MII d’AbbVie 2026. Cette année...
April 02, 2026 11:00 ET | Source: Crohn's and Colitis Canada

AbbVie IBD Scholarship Program Marks 15 Years: Applications Open for 2026

Crohn’s and Colitis Canada and AbbVie open applications for the 2026 AbbVie IBD Scholarship, marking 15 years of supporting students living with IBD.
March 13, 2026 07:53 ET | Source: Research and Markets

Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Zymfentra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...
February 24, 2026 07:03 ET | Source: Research and Markets

Inflammatory Bowel Disease Treatment Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Launches, Sustainability Goals, Revenue Insights

Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights,...
February 20, 2026 08:00 ET | Source: AltruBio Inc.

AltruBio Announces Formation of Inflammatory Bowel Disease Clinical Advisory Board

SAN FRANCISCO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company developing novel immune checkpoint enhancers to address the unmet need...
February 19, 2026 16:02 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second...
February 18, 2026 10:28 ET | Source: Research and Markets

JAK Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 40+ Companies and 45+ Drugs by Company, Product Type, Development Stage, Administration Route, Molecule Type

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "JAK Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers a detailed analysis of over...
February 18, 2026 09:33 ET | Source: Stoked Bio Inc.

Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease

Stoked Bio, a Canadian biotech company, will lead the development of Enterololin, a promising antibiotic, as a potential therapeutic for Crohn’s disease.
February 17, 2026 06:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well...